Sequence Alterations in the Carboxyl- Terminal Propeptide Do main - Osteogenesis Imperfecta - page 125

formation and result in several types of osteogenesis imperfecta.
Hum Mutat 2001;18(4):319-26.
[48] Swinnen FK, De Leenheer EM, Coucke PJ, Cremers CW,
Dhooge IJ. Audiometric, surgical, and genetic indings in 15
ears of patients with osteogenesis imperfecta. Laryngoscope
2009;119(6):1171-9.
[49] Lamande SR, Bateman JF. The type I collagen pro alpha
1(I) COOH-terminal propeptide N-linked oligosaccharide.
Functional analysis by site-directed mutagenesis. J Biol Chem
1995;270(30):17858-65.
[50] Bateman JF, Mascara T, Cole WG, Stacey A, Jaenisch R. Collagen
protein abnormalities produced by site-directed mutagenesis of
the pro alpha 1(I) gene. Connect Tissue Res 1989;20(1-4):205-12.
discussion 61-3.
[51] Hartikka H, Kuurila K, Korkko J, et al. Lack of correlation
between the type of COL1A1 or COL1A2 mutation and hear-
ing loss in osteogenesis imperfecta patients. Hum Mutat 2004;
24(2):147-54.
[52] Bodian DL, Chan TF, Poon A, et al. Mutation and polymor-
phism spectrum in osteogenesis imperfecta type II: implica-
tions for genotype-phenotype relationships. Hum Mol Genet
2009;18(3):463-71.
[53] Takagi M, Hori N, Chinen Y, et al. Heterozygous C-propeptide
mutations in COL1A1: osteogenesis imperfecta type IIC and
dense bone variant. Am J Med Genet A 2011;155A(9):2269-73.
[54] Fuccio A, Iorio M, Amato F, et al. A novel DHPLC-based pro-
cedure for the analysis of COL1A1 and COL1A2 mutations in
osteogenesis imperfecta. J Mol Diagn 2011;13(6):648-56.
[55] Rugolotto S, Monti E, Carli M, Pietrobelli A, Antoniazzi F,
Tato L. Pulmonary function tests in an infant with osteogen-
esis imperfecta and early biphosphonate treatment. Acta Paediatr
2007;96(12):1856-7.
[56] Ke LF, Zheng LW, Xie HH, Yan AZ, Zhu ZY, Lan FH. Molecular
diagnosis of a Chinese pedigree with osteogenesis imperfecta
type I. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2009;26(1):50-3.
[57] Pace JM, Chitayat D, Atkinson M, Wilcox WR, Schwarze U,
Byers PH. A single amino acid substitution (D1441Y) in the car-
boxyl-terminal propeptide of the proalpha1(I) chain of type I col-
lagen results in a lethal variant of osteogenesis imperfecta with
features of dense bone diseases. J Med Genet 2002;39(1):23-9.
[58] Roschger P, Fratzl-Zelman N, Misof BM, Glorieux FH, Klaushofer
K, Rauch F. Evidence that abnormal high bone mineralization in
growing children with osteogenesis imperfecta is not associated
with speciic collagen mutations. Calcif Tissue Int 2008;82(4):263-70.
[59] Benusiene E, Kucinskas V. COL1A1 mutation analysis in
Lithuanian patients with osteogenesis imperfecta. J Appl Genet
2003;44(1):95-102.
[60] Willing MC, Cohn DH, Byers PH. Frameshift mutation near the
3′ end of the COL1A1 gene of type I collagen predicts an elon-
gated Pro alpha 1(I) chain and results in osteogenesis imperfecta
type I. J Clin Invest 1990;85(1):282-90.
[61] Oliver JE, Thompson EM, Pope FM, Nicholls AC. Mutation in
the carboxy-terminal propeptide of the Pro alpha 1(I) chain of
type I collagen in a child with severe osteogenesis imperfecta (OI
type III): possible implications for protein folding. Hum Mutat
1996;7(4):318-26.
[62] Li C. Increased bone mineral density and body mass index
in families with osteogenesis imperfecta: a new type of OI?
Honolulu, Hawai'i: ASHG; 2009.
[63] Pace JM, Wiese M, Drenguis AS, et al. Defective C-propeptides
of the proalpha2(I) chain of type I procollagen impede molecu-
lar assembly and result in osteogenesis imperfecta. J Biol Chem
2008;283(23):16061-7.
[64] Ponnapakkam TP, Sledge D, Gensure R. A novel COL1A2 muta-
tion leading to osteogenesis imperfecta Type 1 in identical
twins. Pediatrics, Ochsner Clinic Foundation; New Orleans, LA.

[65] Schwarze U, Hata R, McKusick VA, et al. Rare autosomal reces-

sive cardiac valvular form of Ehlers-Danlos syndrome results
from mutations in the COL1A2 gene that activate the non-
sense-mediated RNA decay pathway. Am J Hum Genet 2004;
74(5):917-30.

[66] McNeeley MF, Dontchos BN, Lalamme MA, Hubka M, Sadro CT.

Aortic dissection in osteogenesis imperfecta: case report and review
of the literature. Emerg Radiol 2012;19(6):553-6.

[67] Pihlajaniemi T, Dickson LA, Pope FM, et al. Osteogenesis imper-

fecta: cloning of a pro-alpha 2(I) collagen gene with a frameshift
mutation. J Biol Chem 1984;259(21):12941-4.

[68] Zhang ZL, Zhang H, Ke YH, et al. The identiication of novel

mutations in COL1A1, COL1A2, and LEPRE1 genes in Chinese
patients with osteogenesis imperfecta. J Bone Miner Metab
2012;30(1):69-77.

[69] Venturi G, Tedeschi E, Mottes M, et al. Osteogenesis imper-

fecta: clinical, biochemical and molecular indings. Clin Genet
2006;70(2):131-9.

[70] Bateman JF, Lamande SR, Dahl HH, Chan D, Mascara T, Cole WG.

A frameshift mutation results in a truncated nonfunctional car-
boxyl-terminal pro alpha 1(I) propeptide of type I collagen in osteo-
genesis imperfecta. J Biol Chem 1989;264(19):10960-4.

[71] Pace JM, Kuslich CD, Willing MC, Byers PH. Disruption of one

intra-chain disulphide bond in the carboxyl-terminal propep-
tide of the proalpha1(I) chain of type I procollagen permits slow
assembly and secretion of overmodiied, but stable procolla-
gen trimers and results in mild osteogenesis imperfecta. J Med
Genet 2001;38(7):443-9.

[72] Mizuno M, Fujisawa R, Kuboki Y. The effect of carboxyl-ter-

minal propeptide of type I collagen (c-propeptide) on collagen
synthesis of preosteoblasts and osteoblasts. Calcif Tissue Int
2000;67(5):391-9.

[73] Mizuno M, Fujisawa R, Kuboki Y. Carboxyl-terminal propep-

tide of type I collagen (c-propeptide) modulates the action
of TGF-beta on MC3T3-E1 osteoblastic cells. FEBS Lett 2000;
479(3):123-6.

[74] Wu CH, Donovan CB, Wu GY. Evidence for pretranslational reg-

ulation of collagen synthesis by procollagen propeptides. J Biol
Chem 1986;261(23):10482-4.

[75] Deak SB, Nicholls A, Pope FM, Prockop DJ. The molecular defect

in a nonlethal variant of osteogenesis imperfecta. Synthesis of
pro-alpha 2(I) chains which are not incorporated into trimers of
type I procollagen. J Biol Chem 1983;258(24):15192-97.

[76] Chipman SD, Sweet HO, McBride Jr DJ, et al. Defective pro

alpha 2(I) collagen synthesis in a recessive mutation in mice: a
model of human osteogenesis imperfecta. Proc Natl Acad Sci
USA 1993;90(5):1701-5.

[77] Campbell BG, Wootton JA, Macleod JN, Minor RR. Canine

COL1A2 mutation resulting in C-terminal truncation of pro-
alpha2(I) and severe osteogenesis imperfecta. J Bone Miner Res
2001;16(6):1147-53.

[78] Malfait F, Symoens S, Coucke P, Nunes L, De Almeida S, De Paepe

A. Total absence of the alpha2(I) chain of collagen type I causes a
rare form of Ehlers-Danlos syndrome with hypermobility and pro-
pensity to cardiac valvular problems. J Med Genet 2006;43(7):e36.

[79] Asharani PV, Keupp K, Semler O, et al. Attenuated BMP1 func-

tion compromises osteogenesis, leading to bone fragility in
humans and zebraish. Am J Hum Genet 2012;90(4):661-74.

[80] Anelli T, Sitia R. Protein quality control in the early secretory

pathway. EMBO J 2008;27(2):315-27.

[81] Bateman JF, Boot-Handford RP, Lamande SR. Genetic diseases

of connective tissues: cellular and extracellular effects of ECM
mutations. Nat Rev Genet 2009;10(3):173-83.

[82] Boot-Handford RP, Briggs MD. The unfolded protein response

and its relevance to connective tissue diseases. Cell Tissue Res
2010;339(1):197-211.